CA2967662C - Formulation sublinguale de riluzole - Google Patents

Formulation sublinguale de riluzole

Info

Publication number
CA2967662C
CA2967662C CA2967662A CA2967662A CA2967662C CA 2967662 C CA2967662 C CA 2967662C CA 2967662 A CA2967662 A CA 2967662A CA 2967662 A CA2967662 A CA 2967662A CA 2967662 C CA2967662 C CA 2967662C
Authority
CA
Canada
Prior art keywords
disorder
disorders
riluzole
sublingual
oral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2967662A
Other languages
English (en)
Other versions
CA2967662A1 (fr
Inventor
Vladimir Coric
Robert M. Berman
Ronald Samuel Vladyka
Amgad Saleh
Danny Yu
Original Assignee
Biohaven Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Therapeutics Ltd filed Critical Biohaven Therapeutics Ltd
Priority claimed from PCT/US2015/061114 external-priority patent/WO2016081472A1/fr
Publication of CA2967662A1 publication Critical patent/CA2967662A1/fr
Application granted granted Critical
Publication of CA2967662C publication Critical patent/CA2967662C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

L'invention concerne l'administration sublinguale de riluzole. En particulier, l'invention concerne un procédé de traitement d'un trouble ou d'un symptôme neuropsychiatrique par administration d'une formulation sublinguale de riluzole. En outre, l'invention concerne un procédé permettant de soulager ou de réduire la douleur par voie orale à l'aide de la formulation sublinguale de riluzole.
CA2967662A 2014-11-21 2015-11-17 Formulation sublinguale de riluzole Active CA2967662C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462083094P 2014-11-21 2014-11-21
US62/083,094 2014-11-21
PCT/US2015/061114 WO2016081472A1 (fr) 2014-11-21 2015-11-17 Formulation sublinguale de riluzole

Publications (2)

Publication Number Publication Date
CA2967662A1 CA2967662A1 (fr) 2016-05-26
CA2967662C true CA2967662C (fr) 2026-04-28

Family

ID=

Similar Documents

Publication Publication Date Title
AU2021201034B2 (en) Sublingual formulation of riluzole
US20180153862A1 (en) Sublingual administration of riluzole
Leboyer et al. Brief report: A double-blind study of naltrexone in infantile autism
WO2008097924A2 (fr) Compositions pharmaceutiques comprenant des analogues du dextrométhorphane pour le traitement de troubles neurologiques
JP2024010017A (ja) 疾患処置のためのリルゾール口腔内崩壊錠の使用
US11583517B2 (en) Dual antagonist of PGD2/DPr2 and Thromboxane A2/TPr receptors and use for treatment of maladaptive immune response or thrombotic diathesis
CA2967662C (fr) Formulation sublinguale de riluzole
JP2022527865A (ja) ストレスに対するセロトニン４受容体アゴニストの予防的有効性
HK40077183A (en) Sublingual formulation of riluzole
HK40024978A (en) Sublingual formulation of riluzole
HK40024978B (en) Sublingual formulation of riluzole
HK1243318A1 (en) Sublingual formulation of riluzole
HK1243318B (en) Sublingual formulation of riluzole